Related Experiment Videos
[Treatment of hepatitis C]
C Trepo1, F Habersetzer, F Bailly
1Service d'Hépato-Gastroentérologie, Hôpital Hôtel-Dieu, LYON, France.
Pathologie-Biologie
|October 1, 1995
Summary
Alpha interferon therapy for hepatitis C virus (HCV) shows moderate success, with relapse rates around 25%. New treatments, including interferon combinations, are crucial for improving patient outcomes and managing non-responders.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis C virus (HCV) treatment primarily relies on interferon alpha.
- Initial trials show ~50% response to interferon alpha, with 25% relapse, normalizing liver enzymes and improving histology.
Purpose of the Study:
- To evaluate factors influencing interferon alpha treatment response in chronic hepatitis C.
- To identify optimal treatment regimens and explore alternative therapies for non-responders.
Main Methods:
- Analysis of treatment duration, dosage, disease duration, cirrhosis, and viral markers (genotype 1b, viral load).
- Review of outcomes including biochemical normalization, histological improvement, and viral clearance.
Main Results:
- Treatment response is influenced by duration, dose, disease duration, cirrhosis, genotype 1b, and high viral load.
- Longer treatment courses (12 months) and higher doses show improved efficacy.
- Virological markers like genotype and viral load impact response rates but don't predict individual outcomes.
Conclusions:
- Defining pre-treatment response scores is essential for personalized therapy.
- Development of new treatments, such as interferon combinations (e.g., ribavirin and interferon alpha bitherapy), is critical for enhanced efficacy.